Venture
Capstan Therapeutics, Inc.
Latest Form D 2024-03-20- CIK 2015437
- State CA
- Biotechnology
- 3 Form D offerings since 2024-03-20
- Total sold
- $227M
- across 3 offerings
- Rounds
- 3
- Form D offerings since 2024-03-20
- Latest round
- $87.5M
- 2024-03-20 · 021-508077
- Investors
- 21
- on the latest round
Connected
named in its Form D filingsOfferings · since 2024-03-203 Form D offeringsExemptions506(b)People · Item 3Laura Shawver + 13 moreInvestors · dashboardInferred investors
Capstan Therapeutics, Inc.CIK 2015437
Round timeline
amount sold · by first filed2024-03-20 · $87.5M
- 2024-03-20$63M021-508075
- 2024-03-20$76.5M021-508076
- 2024-03-20$87.5M021-508077
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($87.5M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-508077 | First filed2024-03-20 | Latest2024-03-20 | Sought$175M | Sold$87.5M | Investors21 | Exemptions506(b) |
| 021-508076 | First filed2024-03-20 | Latest2024-03-20 | Sought$102M | Sold$76.5M | Investors14 | Exemptions506(b) |
| 021-508075 | First filed2024-03-20 | Latest2024-03-20 | Sought$63M | Sold$63M | Investors9 | Exemptions506(b) |
Who backs Capstan Therapeutics, Inc., inferred from co-filings, and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2024-03-20
| Name | Relationship |
|---|---|
| Laura Shawver | RelationshipExecutive Officer, Director |
| Justin Thacker | RelationshipExecutive Officer |
| Ramin Farzaneh-Far | RelationshipExecutive Officer |
| Adrian Bot | RelationshipExecutive Officer |
| Priya Karmali | RelationshipExecutive Officer |
| Michael Baran | RelationshipDirector |
| Erez Chimovits | RelationshipDirector |
| Rajul Jain | RelationshipDirector |
| Nandita Shangari | RelationshipDirector |
| Karen Smith | RelationshipDirector |
| Athena Countouriotis | RelationshipDirector |
| Michal Silverberg | RelationshipDirector |
| Fabio Pucci | RelationshipDirector |
| Nanna Luneborg | RelationshipDirector |
Facts
As its latest Form D states them
- Industry
- Biotechnology
- State
- California (CA)
- Exemptions
- Rule 506(b)
- First filed
- 2024-03-20
- Latest filing
- 2024-03-20
Who backs Capstan Therapeutics, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗